<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5301">
  <stage>Registered</stage>
  <submitdate>6/12/2015</submitdate>
  <approvaldate>6/12/2015</approvaldate>
  <nctid>NCT02636972</nctid>
  <trial_identification>
    <studytitle>The Progression From Dysmenorrhoea to Chronic Pelvic Pain</studytitle>
    <scientifictitle>The Progression From Dysmenorrhoea to Chronic Pelvic Pain: Investigation of the Role of Chronic Inflammatory Pain Phenotype in Peripheral Blood as a Potential Biomarker.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PPAI-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Dysmenorrhoea</healthcondition>
    <healthcondition>Pelvic Pain</healthcondition>
    <healthcondition>Chronic Pain</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Menstruation and menopause</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - OCPs

Group 1 - Mild or absent dysmenorrhoea and no other pelvic pain symptoms without contraceptive pill use.

Group 2A - History of mild or absent dysmenorrhoea prior to pill use and no other pelvic pain symptoms with contraceptive pill use (Participants already using contraceptive pills).

Group 2B - History of severe dysmenorrhoea prior to pill use and no other pelvic pain symptoms with contraceptive pill use (Participants already using contraceptive pills).

Group 3 - Severe dysmenorrhoea but without chronic pelvic pain and without contraceptive pill use.

Group 4 - Severe dysmenorrhoea but without chronic pelvic pain and with contraceptive pill use (Participants already using contraceptive pills).

Group 5 - Chronic pelvic pain and severe dysmenorrhoea without contraceptive pill use

Group 6 - Chronic pelvic pain and severe dysmenorrhoea with contraceptive pill use (Participants already using contraceptive pills).


Treatment: drugs: OCPs
Participants in the contraceptive pill groups can use any one of the following contraceptive pills:
Oestradiol valerate and dienogest, drospirenone and ethinyl estradiol , ethinyloestradiol and levonorgestrel, cyproterone and ethinyl estradiol, ethinylestradiol and norethisterone, Nomegestrol Acetate and Oestradiol and Ethinyl Estra

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Reactivity of stimulated isolated peripheral blood immune cells - To determine if there are different inflammatory pain phenotypes between young women with either severe dysmenorrhoea alone, chronic pelvic pain from controls with mild or no dysmenorrhoea from the collected peripheral blood immune cells (assessed by cytokine output).</outcome>
      <timepoint>2 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Impact of pelvic pain on everyday activities using the Pelvic Pain Questionnaire - Secondary efficacy end point</outcome>
      <timepoint>2 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Levels of anxiety and depression using the DAS21 - Secondary efficacy end point</outcome>
      <timepoint>2 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age between 16 to 35 years old</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>35</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Irregular menstrual cycles

          -  Use of any reproductive hormonal preparations (other than the combined oral
             contraceptive pill), thyroxine, insulin or corticosteroids

          -  Presence of an inflammatory process, or clinically significant infection in the 4
             weeks

          -  Clinically significant renal, hepatic, cardiac, auto-immune disease

          -  Current use of immunosuppressant medication such as hydroxychloroquine, methotrexate
             or azathioprine

          -  Inability to read or comprehend the written information provided

          -  Current use of medications known to affect TLR responsiveness including amitriptyline
             or minocycline

          -  Current use of any analgesics, including non-steroidal anti-inflammatory medications
             and opioids for 5 drug half-lives prior to the day of testing

          -  Current or previous pregnancy

          -  Body Mass index less than 18 or more than 30</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration>Cross-sectional</duration>
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>56</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/01/2016</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>PARC, Royal Adelaide Hospital - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University of Adelaide</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a cross-sectional observational study.

      For participants resident in Adelaide, South Australia.

      The study consists of 3 visits to the Pain and Anaesthesia Research Clinic (PARC), within the
      Royal Adelaide Hospital (RAH).

      A total of 56 participants will be recruited for this study.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02636972</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Susan Evans, MBBS</name>
      <address>PARC Research Clinic</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>